profit from every CHF 100 of sales.
CHF 0CHF 100
Galderma Group
CHF 194.95+3.39% today
+16.9% in 1 year
1-year low CHF 142.101-year high CHF 195.15
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay CHF 89.09 for every CHF 1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Galderma Group sold, what it kept, and what it did with the cash.
Sales went from $3.82 billion in 2022 to $5.24 billion in 2025, with $613 million of profit last year.
SalesProfit
Galderma Group handed back 39% of the cash it generated last year.
Buybacks $363M
Free cash flow 2025$1.0B
Bought back its own shares$363M
Paid as dividends$41M
Cash vs. debt$780M vs. $2.8B
Galderma Group vs. similar companies
Galderma Group grows the fastest of these 5 and is priced in the middle for its profits.
| Company | Profit from CHF 100 of sales | Sales growth a year | Price per CHF 1 of profit |
|---|---|---|---|
| Galderma Group | 89.1× · Very expensive | ||
 Merck KGaA | 25.9× · Fair price | ||
 Takeda Pharmaceutical | 98.8× · Very expensive | ||
 Teva Pharmaceutical Industries | 35.8× · Expensive | ||
 Sun Pharmaceutical Industries | 39.8× · Expensive |
AI analysis
An AI analyst reads Galderma Group's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 3,824 | 4,117 | 4,440 | 5,241 | |
| 2,630 | 2,885 | 3,085 | 3,609 | |
| 406 | 611 | 678 | 876 | |
| 624 | 851 | 959 | 1,136 | |
| -99 | -57 | 231 | 613 | |
| -0.41 | -0.24 | 0.97 | – | |
| 68.8% | 70.1% | 69.5% | 68.9% | |
| 10.6% | 14.8% | 15.3% | 16.7% | |
| -2.6% | -1.4% | 5.2% | 11.7% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | – | 12,471 | 12,617 | 13,393 |
| Cash | – | 368 | 457 | 780 |
| Total debt | – | 4,909 | 2,760 | 2,754 |
| Total liabilities | – | 7,102 | 4,827 | 5,244 |
| – | 5,369 | 7,790 | 8,150 | |
| 238 | 238 | 238 | – | |
| – | 4.8% | 5.4% | 6.3% | |
| – | -1.1% | 3.0% | 7.5% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 111 | 165 | 488 | 1,185 | |
| 160 | 153 | 275 | 154 | |
| -48 | 12 | 213 | 1,031 | |
| Dividends paid | – | – | – | 41 |
| – | 0 | 15 | 363 | |
| – | 0 | 68 | 64 |
Valuation
- 89.1×
- –
- –
- 6.7×
- 10.4×
- 53.0×
- 49.8×
- 1.9%
- 1.1%
- 0.1%
Profitability
- 68.9%
- 16.7%
- 11.7%
- –
- 6.3%
- 5.5%
- –
- –
- –
- –
Growth
- +11.1%
- –
- –
- –
- +0.0%
Financial health
- 1.7×
- 0.34
- –
- 4.6×
- 1.19
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 46%of 958
Top 30%of 888
Bottom 11%of 600
Top 49%of 889
Top 44%of 987
0.1%of the share price, paid each year
On $1,000 invested$1a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
6.7% of its profit
Room to growStretchedMore than it earns: 4.0%
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
40No pass
Benjamin Graham
18No pass
Philip Fisher
45No pass
Peter Lynch
63Pass
Joel Greenblatt
3No pass
Charlie Munger
38No pass
Terry Smith
42No pass
Questions about Galderma Group
Is Galderma Group a good stock to buy?
A solid business, priced as if everything goes right. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Galderma Group AI analysis
What does Galderma Group do?
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It is in Drug Manufacturers - Specialty & Generic, based in Zug, Switzerland, with 7,676 employees.
Does Galderma Group pay a dividend?
Yes. At today's price the dividend is 0.1% a year, about 7% of its yearly profit. In 2025 it paid out CHF 41.0 million in dividends.
Is Galderma Group stock halal?
Yes. Galderma Group passes our halal screen: its business is permitted and its debt is 5% of its market value, under the 30% limit. How we check
How has Galderma Group stock done over the past year?
Up 16.9% over the past twelve months, to CHF 194.95. It traded between CHF 142.10 and CHF 195.15, close to its high.
Who are Galderma Group's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Teva Pharmaceutical Industries and Sun Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Galderma Group's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.